G1 Therapeutics, Inc. (NASDAQ:GTHX) management will conduct a conference call for 4th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.g1therapeutics.com
Earnings Expectation
G1 Therapeutics, Inc. is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.3 per share from revenue of $ 28.57 million. Looking ahead, the full year loss are expected at $ 2.91 per share on the revenues of $ 27.09 million.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
